{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:49Z","timestamp":1792271389916,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,18]]},"DOI":"10.7759\/cureus.12759","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T12:25:38Z","timestamp":1610972738000},"source":"Crossref","is-referenced-by-count":76,"title":["Adverse Effects Associated with Proton Pump Inhibitor Use"],"prefix":"10.7759","author":[{"given":"Marcel","family":"Yibirin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"De Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Valera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E","family":"Plitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Lutgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg DE","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017, 152:706-715. 10.1053\/j.gastro.2017.01.031","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long\u2010term proton pump inhibitor use: a review","volume":"123","author":"Haastrup PF","year":"2018","unstructured":"Haastrup PF, Thompson W, S\u00f8ndergaard J, Jarb\u00f8l DE. Side effects of long\u2010term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018, 123:114-121. 10.1111\/bcpt.13023","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02854-8","article-title":"Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis","volume":"76","author":"Song HJ","year":"2020","unstructured":"Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020, 76:851-866. 10.1007\/s00228-020-02854-8","journal-title":"Eur J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205203","article-title":"Adverse effects of proton pump inhibitors\u2014evidence and plausibility","volume":"20","author":"Fossmark R","year":"2019","unstructured":"Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors\u2014evidence and plausibility. Int J Mol Sci. 2019, 20:5203. 10.3390\/ijms20205203","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S130568","article-title":"Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies","volume":"11","author":"Yang Y","year":"2017","unstructured":"Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Devel Ther. 2017, 11:1291-1299. 10.2147\/DDDT.S130568","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw470","article-title":"The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis","volume":"33","author":"Nochaiwong S","year":"2018","unstructured":"Nochaiwong S, Ruengorn C, Awiphan R, et al.. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018, 33:331-342. 10.1093\/ndt\/gfw470","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4725-5","article-title":"Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis","volume":"62","author":"Wijarnpreecha K","year":"2017","unstructured":"Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P, Cheungpasitporn W. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017, 62:2821-2827. 10.1007\/s10620-017-4725-5","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1992.262.4.c963","article-title":"Plasma membrane Na+-H+ antiporter and H+-ATPase in the medullary thick ascending limb of rat kidney","volume":"262","author":"Froissart M","year":"1992","unstructured":"Froissart M, Borensztein P, Houillier P, et al.. Plasma membrane Na+-H+ antiporter and H+-ATPase in the medullary thick ascending limb of rat kidney. Am J Physiol Cell Physiol. 1992, 262:C963-C970. 10.1152\/ajpcell.1992.262.4.c963","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543501","article-title":"Omeprazole, a gastric \u2018proton pump inhibitor\u2019: lack of effect on renal handling of electrolytes and urinary acidification","volume":"26","author":"Howden CW","year":"1984","unstructured":"Howden CW, Reid JL. Omeprazole, a gastric \u2018proton pump inhibitor\u2019: lack of effect on renal handling of electrolytes and urinary acidification. Eur J Clin Pharmacol. 1984, 26:639-640. 10.1007\/BF00543501","journal-title":"Eur J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard J","year":"2007","unstructured":"Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007, 102:2047-2056.","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok CS","year":"2012","unstructured":"Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012, 107:1011-1019. 10.1038\/ajg.2012.108","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.42","article-title":"Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection","volume":"175","author":"McDonald EG","year":"2015","unstructured":"McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection. JAMA Intern Med. 2015, 175:784-791. 10.1001\/jamainternmed.2015.42","journal-title":"JAMA Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0084-3873(12)00271-4","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection","volume":"2012","author":"DeVault KR","year":"2012","unstructured":"DeVault KR. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Yearb Med. 2012, 2012:367-368. 10.1016\/s0084-3873(12)00271-4","journal-title":"Yearb Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.89","article-title":"Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection","volume":"170","author":"Howell MD","year":"2010","unstructured":"Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010, 170:784-790. 10.1001\/archinternmed.2010.89","journal-title":"Arch Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.06.019","article-title":"Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations","author":"Koyyada A","year":"2020","unstructured":"Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapies. 2020, 10.1016\/j.therap.2020.06.019","journal-title":"Therapies"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322248","article-title":"Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching","volume":"70","author":"Lee SW","year":"2021","unstructured":"Lee SW, Ha EK, Yeniova A\u00d6, et al.. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021, 70:76-84. 10.1136\/gutjnl-2020-322248","journal-title":"Gut"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000798","article-title":"Increased risk of COVID-19 among users of proton pump inhibitors","volume":"115","author":"Almario CV","year":"2020","unstructured":"Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020, 115:1707-1715. 10.14309\/ajg.0000000000000798","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2015.1054426","article-title":"Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?","volume":"50","author":"Cavalcoli F","year":"2015","unstructured":"Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?. Scand J Gastroenterol. 2015, 50:1397-1403. 10.3109\/00365521.2015.1054426","journal-title":"Scand J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers N","year":"2017","unstructured":"Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017, 7:e017739. 10.1136\/bmjopen-2017-017739","journal-title":"BMJ Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102444","article-title":"The enterochromaffin-like [ECL] cell\u2014central in Gastric physiology and pathology","volume":"20","author":"Waldum HL","year":"2019","unstructured":"Waldum HL, S\u00f8rdal \u00d8F, Mj\u00f8nes PG. The enterochromaffin-like [ECL] cell\u2014central in Gastric physiology and pathology. Int J Mol Sci. 2019, 20:2444. 10.3390\/ijms20102444","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.007","article-title":"Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study","volume":"152","author":"Tsai CF","year":"2017","unstructured":"Tsai CF, Chen MH, Wang YP, et al.. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology. 2017, 152:134-141. 10.1053\/j.gastro.2016.09.007","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v11.i6.522","article-title":"Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients","volume":"11","author":"Fasullo M","year":"2019","unstructured":"Fasullo M, Rau P, Liu DQ, Holzwanger E, Mathew JP, Guilarte-Walker Y, Szabo G. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients. World J Hepatol. 2019, 11:522-530. 10.4254\/wjh.v11.i6.522","journal-title":"World J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12875","article-title":"Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study","volume":"40","author":"Min YW","year":"2014","unstructured":"Min YW, Lim KS, Min BH, et al.. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014, 40:695-704. 10.1111\/apt.12875","journal-title":"Aliment Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14796","article-title":"Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies","volume":"48","author":"Tran KT","year":"2018","unstructured":"Tran KT, McMenamin C, Hicks B, et al.. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018, 48:55-64. 10.1111\/apt.14796","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00796-x","article-title":"Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus","volume":"8","author":"Llorente C","year":"2017","unstructured":"Llorente C, Jepsen P, Inamine T, et al.. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017, 8:837. 10.1038\/s41467-017-00796-x","journal-title":"Nat Commun"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2015.04.003","article-title":"The gut microbiota and liver disease","volume":"1","author":"Llorente C","year":"2015","unstructured":"Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015, 1:275-284. 10.1016\/j.jcmgh.2015.04.003","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80114-7","article-title":"Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma","volume":"30","author":"Caplin M","year":"1999","unstructured":"Caplin M, Khan K, Savage K, et al.. Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J Hepatol. 1999, 30:519-526. 10.1016\/S0168-8278(99)80114-7","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12380","article-title":"Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival","volume":"123","author":"Fossmark R","year":"2015","unstructured":"Fossmark R, Sagatun L, Nordrum IS, Sandvik AK, Waldum HL. Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. APMIS. 2015, 123:509-514. 10.1111\/apm.12380","journal-title":"APMIS"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt278","article-title":"Assessing compound carcinogenicity in vitro using connectivity mapping","volume":"35","author":"Caiment F","year":"2014","unstructured":"Caiment F, Tsamou M, Jennen D, Kleinjans J. Assessing compound carcinogenicity in vitro using connectivity mapping. Carcinogenesis. 2014, 35:201-207. 10.1093\/carcin\/bgt278","journal-title":"Carcinogenesis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong BKS","year":"2019","unstructured":"Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019, 16:1571. 10.3390\/ijerph16091571","journal-title":"Int J Environ Res Public Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4788-y","article-title":"Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies","volume":"30","author":"Poly TN","year":"2019","unstructured":"Poly TN, Islam MM, Yang HC, Wu CC, Li YC. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019, 30:103-114. 10.1007\/s00198-018-4788-y","journal-title":"Osteoporos Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"Vestergaard P","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006, 79:76-83. 10.1007\/s00223-006-0021-7","journal-title":"Calcif Tissue Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi P","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, et al.. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019, 157:682-691.E2. 10.1053\/j.gastro.2019.05.056","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.481","article-title":"Long-term proton pump inhibitor use is not associated with changes in bone strength and structure","volume":"112","author":"Targownik LE","year":"2017","unstructured":"Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017, 112:95-101. 10.1038\/ajg.2016.481","journal-title":"Am J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1963","article-title":"Impaired gastric acidification negatively affects calcium homeostasis and bone mass","volume":"15","author":"Schinke T","year":"2009","unstructured":"Schinke T, Schilling AF, Baranowsky A, et al.. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med. 2009, 15:674-681. 10.1038\/nm.1963","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00366.2016","article-title":"Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells","volume":"312","author":"Al Menhali A","year":"2017","unstructured":"Al Menhali A, Keeley TM, Demitrack ES, Samuelson LC. Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol. 2017, 312:G649-G657. 10.1152\/ajpgi.00366.2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/BF02556841","article-title":"Omeprazole, a specific inhibitor of H+\u2212K+-ATPase, inhibits bone resorptionin vitro","volume":"38","author":"Tuukkanen J","year":"1986","unstructured":"Tuukkanen J, V\u00e4\u00e4n\u00e4nen HK. Omeprazole, a specific inhibitor of H+\u2212K+-ATPase, inhibits bone resorptionin vitro. Calcif Tissue Int. 1986, 38:123-125. 10.1007\/BF02556841","journal-title":"Calcif Tissue Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5257285","article-title":"Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences","author":"Ortiz-Guerrero G","year":"2018","unstructured":"Ortiz-Guerrero G, Amador-Mu\u00f1oz D, Calder\u00f3n-Ospina CA, L\u00f3pez-Fuentes D, Mesa MON. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast. 2018, 10.1155\/2018\/5257285","journal-title":"Neural Plast"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastre.2018.04.013","article-title":"Omeprazole-induced hallucinations. Not as rare as you might think","volume":"41","author":"Sebasti\u00e1n DJJ","year":"2018","unstructured":"Sebasti\u00e1n DJJ. Omeprazole-induced hallucinations. Not as rare as you might think. Gastroenterol Hepatol. 2018, 41:266-267. 10.1016\/j.gastre.2018.04.013","journal-title":"Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058837","article-title":"The proton-pump inhibitor lansoprazole enhances amyloid beta production","volume":"8","author":"Badiola N","year":"2013","unstructured":"Badiola N, Alcalde V, Pujol A, et al.. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013, 8:1-8. 10.1371\/journal.pone.0058837","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom GS","year":"2014","unstructured":"Bloom GS. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014, 71:505-508. 10.1001\/jamaneurol.2013.5847","journal-title":"JAMA Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.11.017","article-title":"Proton pump inhibitors and cardiovascular adverse effects: real or surreal worries?","volume":"72","author":"Manolis AA","year":"2020","unstructured":"Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: real or surreal worries?. Eur J Intern Med. 2020, 72:15-26. 10.1016\/j.ejim.2019.11.017","journal-title":"Eur J Intern Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12698","article-title":"Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction","volume":"283","author":"Sehested TSG","year":"2018","unstructured":"Sehested TSG, Gerds TA, Fosb\u00f8l EL, et al.. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018, 283:268-281. 10.1111\/joim.12698","journal-title":"J Intern Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.08.035","article-title":"Use of proton pump inhibitors and risk of ischemic events in the general population","volume":"277","author":"Casula M","year":"2018","unstructured":"Casula M, Scotti L, Galimberti F, Mozzanica F, Tragni E, Corrao G, Catapano AL. Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis. 2018, 277:123-129. 10.1016\/j.atherosclerosis.2018.08.035","journal-title":"Atherosclerosis"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn W","year":"2015","unstructured":"Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al.. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015, 37:1237-1241. 10.3109\/0886022X.2015.1057800","journal-title":"Ren Fail"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in cardiovascular biology and therapeutics","volume":"16","author":"Dhaun N","year":"2019","unstructured":"Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019, 16:491-502. 10.1038\/s41569-019-0176-3","journal-title":"Nat Rev Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.13.102","article-title":"Chromogranin A as a biomarker in cardiovascular disease","volume":"8","author":"Goetze JP","year":"2014","unstructured":"Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as a biomarker in cardiovascular disease. Biomark Med. 2014, 8:133-140. 10.2217\/bmm.13.102","journal-title":"Biomark Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1530\/EC-14-0027","article-title":"Biological function and clinical relevance of chromogranin A and derived peptides","volume":"3","author":"D'amico MA","year":"2014","unstructured":"D'amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect. 2014, 3:R45-R54. 10.1530\/EC-14-0027","journal-title":"Endocr Connect"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016665641","article-title":"Proton pump inhibitors: risk for myopathy?","volume":"51","author":"Colmenares EW","year":"2017","unstructured":"Colmenares EW, Pappas AL. Proton pump inhibitors: risk for myopathy?. Ann Pharmacother. 2017, 51:66-71. 10.1177\/1060028016665641","journal-title":"Ann Pharmacother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi MF","year":"2017","unstructured":"Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017, 153:35-48. 10.1053\/j.gastro.2017.04.047","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/50133-adverse-effects-associated-with-proton-pump-inhibitor-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:57Z","timestamp":1707507177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/50133-adverse-effects-associated-with-proton-pump-inhibitor-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.12759","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,18]]}}}